The treatments used for chronic lymphocytic leukemia (CLL) have undergone significant changes in the last decade, from using chemoimmunotherapy (CIT), for example, fludarabine, cyclophosphamide, and rituximab (FCR), bendamustine and rituximab (BR), or chlorambucil (Clb)-based treatments such as Clb and obinutuzumab (CO), to fully embracing regimens inclusive of small-molecule-directed therapies (1–3). The gene discussed is CLYBL; the disease is B-cell chronic lymphocytic leukemia.